CA3034258A1 - Ppar.gamma. agonist for treatment of blood cancers - Google Patents

Ppar.gamma. agonist for treatment of blood cancers Download PDF

Info

Publication number
CA3034258A1
CA3034258A1 CA3034258A CA3034258A CA3034258A1 CA 3034258 A1 CA3034258 A1 CA 3034258A1 CA 3034258 A CA3034258 A CA 3034258A CA 3034258 A CA3034258 A CA 3034258A CA 3034258 A1 CA3034258 A1 CA 3034258A1
Authority
CA
Canada
Prior art keywords
leukemia
subject
therapeutically effective
effective amount
milligrams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3034258A
Other languages
English (en)
French (fr)
Inventor
Christos Mantzoros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intekrin Therapeutics Inc
Original Assignee
Intekrin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intekrin Therapeutics Inc filed Critical Intekrin Therapeutics Inc
Publication of CA3034258A1 publication Critical patent/CA3034258A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3034258A 2016-08-18 2017-08-18 Ppar.gamma. agonist for treatment of blood cancers Pending CA3034258A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376749P 2016-08-18 2016-08-18
US62/376,749 2016-08-18
PCT/US2017/047578 WO2018035446A1 (en) 2016-08-18 2017-08-18 PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS

Publications (1)

Publication Number Publication Date
CA3034258A1 true CA3034258A1 (en) 2018-02-22

Family

ID=61197183

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3034258A Pending CA3034258A1 (en) 2016-08-18 2017-08-18 Ppar.gamma. agonist for treatment of blood cancers

Country Status (12)

Country Link
US (1) US20210379049A1 (https=)
EP (1) EP3500268A4 (https=)
JP (2) JP2019524888A (https=)
KR (1) KR20190064573A (https=)
CN (1) CN110461329A (https=)
AU (1) AU2017313839A1 (https=)
BR (1) BR112019003130A2 (https=)
CA (1) CA3034258A1 (https=)
EA (1) EA201990512A1 (https=)
MX (1) MX2019001979A (https=)
SG (2) SG11201901320WA (https=)
WO (1) WO2018035446A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
WO2020243058A1 (en) * 2019-05-30 2020-12-03 Coherus Biosciences, Inc. Compositions and methods to treat cancer
JP2022104747A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗ウイルス剤
JP2022104746A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗がん剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3018186B1 (ja) * 1999-03-09 2000-03-13 大阪大学長 抗炎症剤、単球系細胞の増殖抑制剤
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
JP2010265216A (ja) * 2009-05-14 2010-11-25 Takeda Chem Ind Ltd 複素環化合物
KR102056756B1 (ko) * 2013-01-30 2019-12-17 인테크린 테라퓨틱스, 아이엔씨. 다발성 경화증의 치료를 위한 PPARγ 작용제
ES2866883T3 (es) * 2016-06-08 2021-10-20 Support Venture Gmbh Combinaciones farmacéuticas para el tratamiento del cáncer

Also Published As

Publication number Publication date
EP3500268A4 (en) 2020-04-15
EA201990512A1 (ru) 2019-08-30
JP2019524888A (ja) 2019-09-05
KR20190064573A (ko) 2019-06-10
AU2017313839A1 (en) 2019-03-07
BR112019003130A2 (pt) 2019-05-21
CN110461329A (zh) 2019-11-15
US20210379049A1 (en) 2021-12-09
MX2019001979A (es) 2019-09-19
SG10202101501PA (en) 2021-03-30
JP2022116304A (ja) 2022-08-09
SG11201901320WA (en) 2019-03-28
WO2018035446A1 (en) 2018-02-22
EP3500268A1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
JP2022116304A (ja) 血液がんの治療のためのPPARγアゴニスト
KR102860817B1 (ko) 트라디피턴트에 의한 치료 방법
EP4008329B1 (en) Isoxazoline compounds for use in treating demodicosis
US20190321364A1 (en) Use of neutrophil elastase inhibitors in liver disease
KR20140056212A (ko) 골수성증식 신생물과 같은 암 치료에서의 파노비노스타트와 룩소리티닙의 조합물
JP6145946B2 (ja) 併用als療法
US20080027052A1 (en) Methods for treating cystic kidney disease
US20240382512A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
CA3100792A1 (en) Methods and compositions for treatment of alzheimer's disease
RU2494736C2 (ru) Комбинация, включающая паклитаксел, для лечения рака яичников
KR20190104542A (ko) 비알코올성 지방성 간 질환의 예방 및 치료약
AU2020275208B2 (en) Formulation of delgocitinib in the form of a cream
US10172857B2 (en) Boosting the effect of methotrexate through the combined use with lipophilic statins
JP2025532582A (ja) 組み合わせ
Aboubakr Evaluation of bioequivalence of two enrofloxacin formulations after intramuscular administration in goats
WO2021023291A1 (zh) 原黄素在肺癌治疗中的应用
KR20210095652A (ko) 스테로이드에 대한 내성을 극복하기 위한 글루타르이미드 유도체
JP2025513474A (ja) 好中球性皮膚疾患の治療
AU2006228870A1 (en) Oxaprozin or closely related compound for the treatment and prevention of
CA2753754C (en) Methods for treating schizophrenia
US20220401459A1 (en) New application of chemokine receptor ccr6 inhibitor in preventing recurrence of psoriasis
WO2020234780A1 (en) Methods of treating asthma using a bruton's tyrosine kinase inhibitor
CN121772919A (zh) 用于达到mTOR抑制剂的有效剂量水平的组合物
JP2025512582A (ja) ジテルペン化合物誘導体またはその塩のアトピー性皮膚炎を予防・治療する医薬品の調製における使用
EP4228754A1 (en) Methods of managing side effects of a vasopressin receptor antagonist therapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220817